Showing results (151-160 of 173) with videos related to
Sort By:
Pageof 18
British Journal of Haematology|June 14, 2001
Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2E Hilgenfeld, H Padilla-Nash, N McNeil, et al.Bone Marrow Transplantation|February 5, 2013
CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCTF Rosenow, A Berkemeier, U Krug, et al.Leukemia|July 3, 2002
Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemiaT Padró, R Bieker, S Ruiz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2004
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia IntergroupR F Schlenk, A Benner, J Krauter, et al.Blood|November 23, 2000
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathwaysM Mizuki, R Fenski, H Halfter, et al.Bone Marrow Transplantation|January 20, 2015
Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCTT Sauer, G Silling, C Groth, et al.Leukemia|February 20, 2004
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemiaC Müller-Tidow, S K Metzelder, H Buerger, et al.Blood|June 11, 1999
Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative GroupT Büchner, W Hiddemann, B Wörmann, et al.Leukemia & Lymphoma|October 1, 1996
Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOGT Haferlach, J M Bennett, H Löffler, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2011
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patientsU Brunnberg, M Mohr, R Noppeney, et al.Pageof 18